Drugs for HAE, MASH Are Among Those Expected to Shake Up Specialty Space
-
Jan 09, 2025
Various specialty drug-treated conditions are expected to gain new competitors this year, including hereditary angioedema and metabolic dysfunction-associated steatohepatitis. New formulations and expanded indications of already approved agents are also set to impact a variety of diseases, bringing valuable treatments to patients and stressing payers’ financial situation even further. Industry experts spoke with AIS Health, a division of MMIT, about what drugs and/or therapeutic categories should be on payers’ radar in 2025.
Read more© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.